IBN (“InvestorBrandNetwork”), an innovative content distributor and multifaceted communications organization with 50+ brands including BioMedWire (“BMW”), today announced that it will be collaborating with Hanson Wade as an official media sponsor for the upcoming 2nd Annual Gene Therapy Patient Engagement Summit. The event is slated to take place from June 7-9, 2022, in Boston, Massachusetts, and unite patient advocacy groups, engagement leaders and the patients themselves to provide insight and honest discussions. During the three-day summit, presentations will be held on a variety of topics, including managing expectations of gene therapy across stakeholders, incorporating the latest regulatory guidelines on patient input, designing and implementing meaningful clinical trials, tackling education and misconceptions in gene therapy and engaging in early development with patient groups. “Our team is excited to be working with Hanson Wade as we raise the visibility of the 2nd Annual Gene Therapy Patient Engagement Summit,” said Jonathan Keim, director of communications. “Hanson Wade has gained a well-deserved reputation as an informational leader in the space. We look forward to featuring the innovations taking place in gene therapy programs where the patient’s experience and voice are vital to the industry’s advancements.”
To view the full press release, visit https://ibn.fm/p0PbX
IBN (“InvestorBrandNetwork”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.
For more information on IBN, visit https://www.InvestorBrandNetwork.com.
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork